How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Coming off psychotropic drugs can cause physical as well as mental withdrawal, resulting in failed withdrawal attempts and unnecessary long-term drug use. The first reports about withdrawal appeared in the 1950s, but although patients have been complaining about psychotropic withdrawal problems for decades, the first tentative acknowledgement by psychiatry only came in 1997 with the introduction of the ‘antidepressant-discontinuation syndrome’. It was not until 2019 that the UK Royal College of Psychiatrists, for the first time, acknowledged that withdrawal can be severe and persistent. Given the lack of a systematic professional response, over the years, patients who were experiencing withdrawal started to work out practical ways to safely come off medications themselves. This resulted in an experience-based knowledge base about withdrawal which ultimately, in The Netherlands, gave rise to the development of person-specific tapering medication (so-called tapering strips). Tapering medication enables doctors, for the first time, to flexibly prescribe and adapt the medication required for responsible and person-specific tapering, based on shared decision making and in full agreement with recommendations in existing guidelines. Looking back, it is obvious that the simple practical solution of tapering strips could have been introduced much earlier, and that the traditional academic strategy of comparisons from randomised trials is not the logical first step to help individual patients. While randomised controlled trials (RCTs) are the gold standard for evaluating interventions, they are unable to accommodate the heterogeneity of individual responses. Thus, a more individualised approach, building on RCT knowledge, is required. We propose a roadmap for a more productive way forward, in which patients and academic psychiatry work together to improve the recognition and person-specific management of psychotropic drug withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overall, there has been scant attention paid to the issue of antidepressant tapering previously in the academic literature,48,53–56 which has been focused primarily on starting medication.57”
The cited source says what the claim attributes to it.
In the citing paper
“Self-monitoring can sometimes add an extra dimension, making the tapering more personalised and more robust to manage early withdrawal.9,29”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Apart from the Horowitz–Taylor tapering method,20 and the work of Peter Groot and Jim van Os in the Netherlands,54–56 there seem to be no good studies on how to safely taper patients off these medications.”
In the citing paper
“National guidelines on tapering of antidepressant and other psychotropic medications, if they exist at all, typically are based on ‘expert opinion’, excluding user knowledge and lived experience, and not very helpful when it comes to the actual process of tapering the medication.1,6,13”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [6]
In the citing paper
“As described elsewhere, rate of tapering can be a very important factor and some individuals may be able to come off medications if a slower and more personalised approach is adopted.9”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lack of group-to-individual generalizability is a threat to human subjects research
Fisher, A. J., Medaglia, J. D., & Jeronimus, B. F. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711978115 · Cited by 1,099
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Tolerating Uncertainty — The Next Medical Revolution?
Simpkin, A. L., & Schwartzstein, R. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606402 · Cited by 521
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
No Shortcuts to Safer Opioid Prescribing
Dowell, D., Haegerich, T., & Chou, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1904190 · Cited by 408
Critical Slowing Down as a Personalized Early Warning Signal for Depression
Wichers, M., Groot, P. C., & Psychosystems, E. G. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441458 · Cited by 399
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Study of Compulsive Buying in Depressed Patients
Lejoyeux, M., Tassain, V., Solomon, J., & AdAs, J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0406 · Cited by 271
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Initiatives to Promote the Discovery of Drugs to Improve Cognitive Function in Severe Mental Illness
Marder, S. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0706e03 · Cited by 218
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Antidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 148
WITHDRAWAL SYMPTOMS FOLLOWING DISCONTINUATION OF IMIPRAMINE THERAPY
KRAMER, J. C., KLEIN, D. F., & FINK, M. (1961) · American Journal of Psychiatry · doi:10.1176/ajp.118.6.549 · Cited by 113
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
Schatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 94
Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Bosman, R. C., Huijbregts, K. M., Verhaak, P. F., Ruhé, H. G., van Marwijk, H. W., van Balkom, A. J., & Batelaan, N. M. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x686641 · Cited by 76
Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · The Journal of Clinical Psychiatry · Cited by 69
Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
Fava, G. A., & Cosci, F. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12794 · Cited by 69
Schatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · PubMed · Cited by 61
The nature of the discontinuation syndrome associated with antidepressant drugs.
Shelton, R. C. (2006) · PubMed · Cited by 60
Antidepressant tapering strips to help people come off medication more safely
Groot, P. C., & van Os, J. (2018) · Psychosis · doi:10.1080/17522439.2018.1469163 · Cited by 55
Self-citationWithdrawal of unnecessary antidepressant medication: a randomised controlled trial in primary care
Eveleigh, R., Muskens, E., Lucassen, P., Verhaak, P., Spijker, J., van Weel, C., Oude Voshaar, R., & Speckens, A. (2018) · BJGP Open · doi:10.3399/bjgpopen17x101265 · Cited by 51
Clinical guidelines on antidepressant withdrawal urgently need updating
Davies, J., Read, J., Hengartner, M. P., Cosci, F., Fava, G., Chouinard, G., van Os, J., Nardi, A., Gøtzsche, P., Groot, P., et al. (2019) · BMJ · doi:10.1136/bmj.l2238 · Cited by 44
Self-citationGroot, P. C. (2010) · Journal of Mental Health · doi:10.3109/09638237.2010.494188 · Cited by 43
Self-citationNICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms
Iacobucci, G. (2019) · BMJ · doi:10.1136/bmj.l6103 · Cited by 42
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
Read, J. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106157 · Cited by 37
Scholten, W. D., Batelaan, N. M., van Oppen, P., Smit, J. H., Hoogendoorn, A. W., van Megen, H. J. G. M., Cath, D. C., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489498 · Cited by 33
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000100 · Cited by 30
Tapering of SSRI treatment to mitigate withdrawal symptoms
Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30182-8 · Cited by 28
Ernst, F. (2015) · Journal of Contemporary Psychotherapy · doi:10.1007/s10879-015-9311-6 · Cited by 27
Gallagher, J. C., Strzinek, R. A., Cheng, R.-F. J., Ausmanas, M. K., Astl, D., & Seljan, P. (2012) · Journal of Women's Health · doi:10.1089/jwh.2011.2764 · Cited by 21
Clinical judgments, not algorithms, are key to patient safety—an essay by David Healy and Dee Mangin
Healy, D., & Mangin, D. A. (2019) · BMJ · doi:10.1136/bmj.l5777 · Cited by 20
Therapy and prevention for mental health: What if mental diseases are mostly not brain disorders?
Ioannidis, J. P. A. (2019) · Behavioral and Brain Sciences · doi:10.1017/s0140525x1800105x · Cited by 15
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
[Taperingstrips for paroxetine and venlafaxine].
Groot, P. C. (2013) · PubMed · Cited by 12
Self-citation[Withdrawal symptoms upon discontinuance of iproniazid and isoniazid therapy].
Selikoff, I. J., Robitzek, E. H., & Ornstein, G. G. (1953) · PubMed · doi:10.1164/art.1953.67.2.212 · Cited by 8
Tackling rising numbers of opioid prescriptions users
Groot, P. C., & van Os, J. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30247-6 · Cited by 4
Self-citation
Research works printed but not linked: 8
- Selikoff IJ, 1953, Am Rev Tuberc, 67, 212
- Schatzberg AF, 1997, J Clin Psychiatry, 58, 23
- Eveleigh R, 2017, BJGP Open, 1
- Groot PC, 2013, Tijdschr Psychiatr, 55, 789
- Scoping about tapering of (specific) antidepressants using tapering strips, Organized by the Dutch National Healthcare Institute
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Schatzberg AF, 2006, J Clin Psychiatry, 67, 27
- Muzina DJ., 2010, Currenty Psychiatry, 9, 51
Cited by
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
“Variables collected were: (1) age (in years), (2) sex, (3) type of medication and duration of use prior to tapering, (4) number of attempts to stop medication before using tapering strips, (5) severity of withdrawal symptoms during previous discontinuation attempts without tapering strips on a 1–7 Likert scale (‘Did y…”
BackgroundSelf-citation
Metadata
- Authors
- Groot, P. C., & van Os, J.
- Affiliations
- University Medical Center Utrecht (NL)
- UMC Utrecht Brain Centre, Utrecht, The Netherlands
- Corresponding author
- Groot, Peter C.
- ORCID
- Groot, Peter C.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320932452-2045125320932452
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7357127
- OpenAlex
- W3040943896
- Cited by
- 49
- References
- 46
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 13 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 5
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Health Professions › General Health Professions › Mental Health and Patient Involvement
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antidepressant discontinuation syndrome, shared decision-making, personalized treatment, patient experience, medication tapering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.